Navarra, Pierluigi

Navarra, Pierluigi  

ROMA - Dipartimento di Sicurezza e Bioetica  

Mostra records
Risultati 1 - 20 di 140 (tempo di esecuzione: 0.017 secondi).
Data di pubblicazione Titolo Autore(i) File
1-gen-2022 Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment Lisi, L.; Lacal, P. M.; Martire, M.; Navarra, P.; Graziani, G.
1-gen-2022 Extended-release calcifediol in stage 3–4 chronic kidney disease: a new therapy for the treatment of secondary hyperparathyroidism associated with hypovitaminosis D Cozzolino, M.; Minghetti, P.; Navarra, P.
1-gen-2022 Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Uncontrolled Oncology Trials: A Comprehensive Review of the Literature Dello Russo, Cinzia; Navarra, Pierluigi
1-gen-2022 The effects of CHF6467, a new mutated form of NGF, on cell models of human glioblastoma. A comparison with wild-type NGF Lisi, Lucia; Ciotti, Gabriella Maria Pia; Chiavari, Marta; Martire, Maria; Navarra, Pierluigi
1-gen-2021 Cell-of-origin and genetic, epigenetic, and microenvironmental factors contribute to the intra-tumoral heterogeneity of pediatric intracranial ependymoma Servidei, T.; Lucchetti, D.; Navarra, P.; Sgambato, A.; Riccardi, R.; Ruggiero, A.
1-gen-2021 Compassionate drug uses and saving for the national health system: the case study of Fondazione Policlinico Gemelli Pilunni, D; Daioisio, V; Campopiano, R; Pani, M; Navarra, P
1-gen-2021 Effects of remifentanil on human C20 microglial pro-inflammatory activation Cappoli, N.; Aceto, P.; Tabolacci, E.; Mezzogori, D.; Sollazzi, L.; Navarra, P.; Dello Russo, C.
1-gen-2021 Kinetics of Intestinal Presence of Spores Following Oral Administration of Bacillus clausii Formulations: Three Single-Centre, Crossover, Randomised, Open-Label Studies Navarra, P.; Milleri, S.; Perez III, M.; Uboldi, M. C.; Pellegrino, P.; Bois De Fer, B.; Morelli, L.
1-gen-2021 Relationship between injection site reactions and different adalimumab formulations. Analysis of the adverse events reported in Italy in 2016-2019 Pilunni, D.; Santuccio, C.; Sottosanti, L.; Felicetti, P.; Navarra, P.
1-gen-2020 A comparison between the assessments of progression-free survival by local investigators versus blinded independent central reviews in phase III oncology trials Dello Russo, C.; Cappoli, N.; Navarra, P.
1-gen-2020 A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB Tringali, G.; Vollono, C.; Calabresi, P.; Navarra, P.
1-gen-2020 Beyond antibodies: ankyrins and DARPins. From basic research to drug approval Caputi, A. P.; Navarra, P.
1-gen-2020 Development of an uplc-ms/ms method for quantitative analysis of clotrimazole in human plasma samples Lisi, L.; Ciotti, G. M. P.; Navarra, P.
1-gen-2020 DNA inhibitors for the treatment of brain tumors Lisi, Lucia; Chiavari, Marta; Ciotti, Gabriella Maria Pia; Lacal, Pedro M; Navarra, Pierluigi; Graziani, Grazia
1-gen-2020 Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Phase 2 Oncology Trials Dello Russo, C.; Cappoli, N.; Pilunni, D.; Navarra, P.
1-gen-2020 Neovascular age-related macular degeneration: Therapeutic management and new-upcoming approaches Ricci, F.; Bandello, F.; Navarra, P.; Staurenghi, G.; Stumpp, M.; Zarbin, M.
1-gen-2020 Pdia3 expression in glioblastoma modulates macrophage/microglia pro-tumor activation Chiavari, M.; Ciotti, G. M. P.; Canonico, F.; Altieri, F.; Lacal, P. M.; Graziani, G.; Navarra, P.; Lisi, L.
1-gen-2020 P2X7 receptors exert a permissive effect on the activation of presynaptic AMPA receptors in rat trigeminal caudal nucleus glutamatergic nerve terminals Curro', D.; Navarra, P.; Samengo, I.; Martire, M.
1-gen-2020 Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections De Pascale, G.; Lisi, L.; Ciotti, G. M. P.; Vallecoccia, M. S.; Cutuli, S. L.; Cascarano, L.; Gelormini, C.; Bello, G.; Montini, L.; Carelli, S.; Di Gravio, V.; Tumbarello, M.; Sanguinetti, M.; Navarra, P.; Antonelli, M.
1-gen-2020 The safety profile of probiotic VSL#3®. A meta-analysis of safety data from double-blind, randomized, placebo-controlled clinical trials Panetta, V.; Bacchieri, A.; Papetti, S.; Stefani, E. D. E.; Navarra, P.